Literature DB >> 22265156

Correlation between plasma pentosidine concentrations and retinal hemodynamics in patients with type 2 diabetes.

Eiichi Sato1, Taiji Nagaoka, Harumasa Yokota, Atsushi Takahashi, Akitoshi Yoshida.   

Abstract

PURPOSE: To investigate whether plasma pentosidine, a well-defined advanced glycation end product, is associated with retinal hemodynamic abnormalities in patients with type 2 diabetes.
DESIGN: Prospective cross-sectional study.
METHODS: Forty-two eyes with type 2 diabetes mellitus were evaluated. The type 2 diabetic eyes were divided into 2 groups: 22 eyes (22 patients; mean age, 61 years) with nondiabetic retinopathy (NDR) and 20 eyes (20 patients; mean age, 61 years) with mild nonproliferative diabetic retinopathy (NPDR). We used a retinal laser Doppler system to measure the arterial diameter, velocity, and blood flow in the major temporal retinal arteries. The pulsatility ratio, a resistive index expressed as the peak systolic to the end diastolic velocity ratio, was calculated from the blood velocity traces. Plasma pentosidine was measured in 42 patients with diabetes using a commercially available competitive enzyme-linked immunosorbent assay.
RESULTS: The pulsatility ratio significantly increased in patients with NPDR (4.8 ± 1.5) compared with patients with NDR (3.7 ± 0.8) (P = .0061). No differences in velocity, diameter, or blood flow were seen between the 2 groups. Plasma pentosidine levels also increased significantly (P = .0085) in patients with NPDR (0.057 ± 0.015) compared to patients with NDR (0.047 ± 0.012). The pulsatility ratio was correlated positively with the plasma pentosidine levels in patients with NPDR (Pearson correlation, r = 0.45, P = .044). Multiple regression analysis showed that the plasma pentosidine level was significantly associated with the pulsatility ratio (standardized coefficient, 0.62; P = .009).
CONCLUSIONS: The vascular rigidity of the retinal arteries may increase with increasing plasma pentosidine in patients with type 2 diabetes with retinopathy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22265156     DOI: 10.1016/j.ajo.2011.10.020

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

Review 1.  Therapeutic targets for altering mitochondrial dysfunction associated with diabetic retinopathy.

Authors:  Renu A Kowluru; Manish Mishra
Journal:  Expert Opin Ther Targets       Date:  2018-03       Impact factor: 6.902

Review 2.  Biomarkers in diabetic retinopathy and the therapeutic implications.

Authors:  Katarzyna Zorena; Dorota Raczyńska; Krystyna Raczyńska
Journal:  Mediators Inflamm       Date:  2013-11-07       Impact factor: 4.711

3.  How Diabetes and Other Comorbidities of Elderly Patients and Their Treatment Influence Levels of Glycation Products.

Authors:  Aleksandra Kuzan; Emilia Królewicz; Irena Kustrzeba-Wójcicka; Karolina Lindner-Pawłowicz; Małgorzata Sobieszczańska
Journal:  Int J Environ Res Public Health       Date:  2022-06-20       Impact factor: 4.614

4.  Effect of insulin treatment on pulsatility ratio and resistance index of the retinal artery in patients with type 2 diabetes.

Authors:  Tsuneaki Omae; Youngseok Song; Takafumi Yoshioka; Tomofumi Tani; Akitoshi Yoshida
Journal:  PLoS One       Date:  2021-07-20       Impact factor: 3.240

Review 5.  Molecular Markers of Diabetic Retinopathy: Potential Screening Tool of the Future?

Authors:  Priyia Pusparajah; Learn-Han Lee; Khalid Abdul Kadir
Journal:  Front Physiol       Date:  2016-06-01       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.